Advertisement

Topics

Corey McPherson Nash Company Profile

16:08 EDT 26th September 2017 | BioPortfolio


News Articles [151 Associated News Articles listed on BioPortfolio]

US FDA rejects Pfizer's Epogen biosimilar citing McPherson site warning

Concerns about Pfizer’s fill/finish plant in McPherson, Kansas have prompted the US FDA to reject the firm’s biosimilar version of Amgen’s anaemia drug Epogen.

GENFIT – The NASH Education ProgramTM annonce le lancement de la première Journée Internationale d’Information sur la NASH, le 12 juin 2018

GENFIT — Thursday, July 13th 2017 at 5:19pm UTC GENFIT – The NASH Education ProgramTM annonce le lancement de la première Journée Internationale d’Information sur la NASH, le 12 ju...

NASH market to expand at a an astonishing CAGR of 45%

The non-alcoholic steatohepatitis (NASH) space across the seven major markets of the USA, France, Germany,…

GENFIT ??? The NASH Education Programtm Announces The Launch Of The First International NASH Information Day On June 12, 2018: Save The Date!

  Life Sciences Jobs   ...

Small-Caps Rushing to Fill the NASH Treatment Pipeline

May 26, 2017 (Investorideas.com Newswire) NASH is an epidemic in the U.S., with more than 100 million people believed to be affected.

Nonalcoholic Steatohepatitis NASH Market Insights, Epidemiology and Market Forecast 2027 [Report Updated: 10072017] Prices from USD $5750

"DelveInsight's Nonalcoholic Steatohepatitis NASH Market Insights, Epidemiology and Market Forecast 2027 Reports provides an overview of the disease and global market size of the NASH for the 7MM Un...

Big Pharma Sets Its Sights on NASH Epidemic

May 18, 2017 (Investorideas.com Newswire) Up to one-third of Americans may have conditions that lead to NASH, yet the disease is far from a household name. Closely linked with obesity, the disease doe...

Can-Fite’s Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment ...

Compelling unmet need for NAFLD/NASH drug to address estimated $35 billion treatment market by 2025 Read more...

PubMed Articles [118 Associated PubMed Articles listed on BioPortfolio]

Nation-wide trends in non-alcoholic steatohepatitis (NASH) in patients with and without diabetes between 2004-05 and 2014-15 in England.

There are no national studies evaluating the epidemiology of non-alcoholic steatohepatitis (NASH) in England. NASH is becoming an increasingly important health issue given the inexorable rise in obesi...

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.

Nonalcoholic steatohepatitis (NASH) is projected to be the leading cause of liver transplantation by 2020. Advanced fibrosis (stage F3-F4) on liver biopsy independently predicts all-cause and liver-re...

A Novel Role of Astrocyte Elevated Gene-1 (AEG-1) in Regulating Non-alcoholic Steatohepatitis (NASH).

Nonalcoholic steatohepatitis (NASH) is the most prevalent cause of chronic liver disease in the Western world. However, an optimum therapy for NASH is yet to be established mandating more in-depth inv...

Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.

Nonalcoholic fatty liver disease (NAFLD) is a major public health concern in western societies. Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, is characterized by hepatic steatosi...

Bile acid alterations are associated with insulin resistance, but not with NASH in obese subjects.

Bile acids (BA) are signalling molecules controlling energy homeostasis which can be both toxic and protective for the liver. BA alterations have been reported in obesity, insulin resistance (IR) and ...

Clinical Trials [110 Associated Clinical Trials listed on BioPortfolio]

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treat...

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH. To gain further ...

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)

TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFLD or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients wit...

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis (BEAT-NASH)

Obesity is an epidemic in the US. With progression of obesity, Nonalcoholic steatohepatitis (NASH) has been a growing public health issue. Presently there is no cure for NASH.Prevention of...

Companies [24 Associated Companies listed on BioPortfolio]

Corey McPherson Nash

Patricia Nash

The quintessential embodiment of style, form and function, Patricia Nash Designs creates handbags and accessories that are made of beautiful, vegetable tanned Italian leather. The...

North American Specialty Hospital

Headquartered in Denver, NASH is a US majority-owned and managed enterprise. Incorporating US physicians in its service delivery, NASH is designed to provide pre-operative and pos...

HARVEY NASH GROUP

Harvey Nash was founded in London in 1988. David Higgins, the current Executive Vice Chairman, was one of the original founders and still has a sizeable financial stake in the company. Early on, the m...

Jake Nash

More Information about "Corey McPherson Nash" on BioPortfolio

We have published hundreds of Corey McPherson Nash news stories on BioPortfolio along with dozens of Corey McPherson Nash Clinical Trials and PubMed Articles about Corey McPherson Nash for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Corey McPherson Nash Companies in our database. You can also find out about relevant Corey McPherson Nash Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record